Hoth Therapeutics Inc (HOTH)

08:38 AM

Hoth Therapeutics partners with VA to test GDNF therapy for obesity By Investing.com - Investing.com South Africa

08:38 AM

08:38 AM

Hoth Therapeutics partners with VA to test GDNF therapy for obesity - Investing.com Australia

08:38 AM

08:19 AM

New Weight Loss Drug Challenger GDNF Takes On Semaglutide in Landmark VA Obesity Study - Stock Titan

08:19 AM

02:17 AM

Why Hoth Therapeutics Inc. stock attracts strong analyst attentionElite Investor Club - Newser

02:17 AM

12:22 PM

Hoth Therapeutics Inc. Stock Analysis and ForecastMarket-crushing stock picks - Autocar Professional

12:22 PM

Jul 21, 2025

Is Hoth Therapeutics Inc. a good long term investmentUnprecedented growth rates - Autocar Professional

Jul 21, 2025

Jul 21, 2025

What analysts say about Hoth Therapeutics Inc. stockFree Stock Selection - Autocar Professional

Jul 21, 2025

Jul 20, 2025

What drives Hoth Therapeutics Inc. stock pricePowerful profit generation - printweek.in

Jul 20, 2025

Jul 15, 2025

How Hoth Therapeutics Inc. stock performs during market volatilitySwing Trade Signals - Newser

Jul 15, 2025

Jul 15, 2025

What makes Hoth Therapeutics Inc. stock price move sharplyDaily Volume Leaders - Newser

Jul 15, 2025

Jul 05, 2025

Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 05, 2025

Jun 25, 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | Daily Courier - FinancialContent

Jun 25, 2025

Jun 24, 2025

Hoth Therapeutics Advances HT-001 for Cancer Treatment - TipRanks

Jun 24, 2025

Jun 24, 2025

HT-001's Breakthrough in Oncology Supportive Care: A Game-Changer for Hoth Therapeutics? - AInvest

Jun 24, 2025

Jun 24, 2025

Hoth Therapeutics stock rises after positive Phase 2a trial results - Investing.com India

Jun 24, 2025

Jun 23, 2025

Leading Cancer Experts Reveal Phase 2 Data for Revolutionary Skin Toxicity Treatment HT-001 - Stock Titan

Jun 23, 2025

Jun 20, 2025

Hoth Therapeutics Regains Nasdaq Compliance on June 18 - TipRanks

Jun 20, 2025

Jun 18, 2025

Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa

Jun 18, 2025

Jun 18, 2025

Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener

Jun 18, 2025

Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com

Jun 18, 2025

Jun 18, 2025

Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan

Jun 18, 2025

Jun 18, 2025

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener

Jun 18, 2025

Jun 18, 2025

Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus

Jun 18, 2025

Jun 18, 2025

Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan

Jun 18, 2025

Jun 18, 2025

Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid By Investing.com - Investing.com India

Jun 18, 2025

Jun 16, 2025

Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX

Jun 16, 2025

Jun 16, 2025

Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan

Jun 16, 2025

Jun 13, 2025

Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus

Jun 13, 2025

Jun 13, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Jun 13, 2025

Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa

Jun 12, 2025

Jun 12, 2025

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener

Jun 12, 2025

Jun 12, 2025

Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com

Jun 12, 2025

Jun 12, 2025

Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan

Jun 12, 2025

Jun 12, 2025

Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus

Jun 12, 2025

Jun 12, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India

Jun 12, 2025

Jun 11, 2025

Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa

Jun 11, 2025

Jun 11, 2025

Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener

Jun 11, 2025

Jun 11, 2025

Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener

Jun 11, 2025

Jun 11, 2025

HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus

Jun 11, 2025

Jun 11, 2025

Hoth Expands Access to Cancer Skin Toxicity Treatment HT-001 in Phase 2a Success | HOTH Stock News - Stock Titan

Jun 11, 2025

Jun 05, 2025

Hoth Therapeutics advances with HT-001 oncology skin care treatment By Investing.com - Investing.com South Africa

Jun 05, 2025

Jun 05, 2025

Hoth Therapeutics advances with HT-001 oncology skin care treatment - Investing.com Australia

Jun 05, 2025

Jun 05, 2025

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities - PR Newswire

Jun 05, 2025

Jun 04, 2025

Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Large Increase in Short Interest - Defense World

Jun 04, 2025